Phase I trial of single doses of IMO 3100 in healthy volunteers.
Phase of Trial: Phase I
Latest Information Update: 05 Apr 2011
At a glance
- Drugs IMO 3100 (Primary)
- Indications Hyperlipidaemia; Psoriasis; Rheumatoid arthritis; Systemic lupus erythematosus
- Focus Adverse reactions
- 05 Apr 2011 Results from this trial have been presented in an Idera Pharmaceuticals media release.
- 15 Feb 2011 Status changed from active, no longer recruiting to completed.
- 08 Jun 2010 Preliminary results have been announced by Idera Pharmaceuticals in a media release. The company plans to present detailed results at a scientific meeting in the fourth quarter of 2010.